睿知中国医院研究地图
候选清单

正在招募胃癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由陆军军医大学第一附属医院(西南医院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方陆军军医大学第一附属医院(西南医院)Southwest Hospital, Army Medical University重庆医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06760858,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.

    入选标准第 3 条

  3. Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.

    入选标准第 1 条

    Received corticosteroids (>10mg/day prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg/day); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.

    排除标准第 9 条

  4. Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.

    入选标准第 2 条

  5. International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.

    入选标准第 6 条

  6. History of HIV infection or active hepatitis B/C virus infection.

    排除标准第 10 条

  7. Pregnant or breastfeeding women.

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06760858,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.
  2. Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.
  3. Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.
  4. Good bone marrow reserve function, with the following blood criteria: white blood cell count ≥3×10\^9/L, neutrophils ≥1.5×10\^9/L, platelet count ≥100×10\^9/L, hemoglobin ≥90 g/L.
  5. Good organ function, with the following biochemical criteria: aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), alanine aminotransferase (ALT) ≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min.
  6. International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.
  7. Urine protein <2+, if urine protein ≥2+ then 24-hour urine protein quantification must be ≤1g.
  8. Consent to provide blood and tissue samples.
  9. Expected survival of more than 3 months.
  10. Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.
  11. Voluntarily sign the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures.

排除标准:Exclusion Criteria:

  1. Participants who have been enrolled in any other drug clinical trial or have participated in any drug clinical trial within the last month.
  2. Any anti-cancer treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than the study medication (palliative external beam radiation for non-target lesions is allowed).
  3. Prior use of similar chemotherapy drugs or immune checkpoint inhibitors.
  4. Presence of metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, or pelvic and abdominal cavity.
  5. Gastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months prior to enrollment.
  6. Other untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients with tumors that have been cured and have no evidence of disease for more than 5 years may be included. All other tumors must have been treated at least 5 years prior to enrollment.
  7. Symptomatic meningiomas:
  8. History of active autoimmune diseases or refractory autoimmune diseases.
  9. Received corticosteroids (>10mg/day prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg/day); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.
  10. History of HIV infection or active hepatitis B/C virus infection.
  11. Persistent > Grade 2 bacterial, fungal, viral infections.
  12. Active or clinically significant cardiac disease:
  13. Congestive heart failure > New York Heart Association (NYHA) Class II;
  14. Active coronary artery disease;
  15. Arrhythmias requiring treatment other than beta-blockers or digoxin;
  16. Unstable angina (angina symptoms at rest), new-onset angina within 3 months prior to enrollment, or unhealed wounds, ulcers, or fractures due to myocardial infarction within 6 months prior to enrollment.
  17. Patients with renal failure requiring hemodialysis or peritoneal dialysis.
  18. Patients requiring medication for epilepsy.
  19. History of organ transplantation (including corneal transplants).
  20. Allergy to the study medication or similar drugs, or suspected allergies.
  21. Pregnant or breastfeeding women.
  22. Major surgery, open biopsy, or significant traumatic surgery within 4 weeks prior to recruitment.
  23. History of vaccination within 4 weeks prior to enrollment.
  24. Patients deemed unsuitable for the study by the investigator.

引自 ClinicalTrials.gov, NCT06760858, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06760858,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06760858